Could Pfizer’s latest cancer breakthrough reshape treatment for colorectal cancer? A new Phase 3 study confirms that adding Braftovi to standard therapy helps patients with BRAF V600E-mutated colorectal cancer live longer without disease progression. This follows an accelerated FDA approval in December, based on earlier data showing a significant tumor response.
With BRAF mutations present in about 10% of colorectal cancer cases, the results could expand treatment options for advanced-stage patients. However, Pfizer has yet to disclose specific survival data.
Pfizer drug acquired in $11B buyout confirms benefit in colon cancer (Biopharma Dive)
0